Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 16Terminated 4Unknown 3Recruiting 2Withdrawn 1Suspended 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 2Prostatic Neoplasms 1Prostate Lesions 1Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × Magnetic Resonance Imaging × Clear all
NCT03987568 2022-12-21

Characterize Tumor Hypoxia by Magnetic Resonance Imaging

Wake Forest University Health Sciences

Phase NA Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡